Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. RYALTRIS NASAL SPRAY 600/25MCG [SIN16523P]

RYALTRIS NASAL SPRAY 600/25MCG [SIN16523P]

Active ingredients: RYALTRIS NASAL SPRAY 600/25MCG

Last updated 26 October 2025

Product Info

RYALTRIS NASAL SPRAY 600/25MCG

[SIN16523P]

Product information

Active Ingredient and Strength

MOMETASONE FUROATE MONOHYDRATE (MICRONIZED) EQV TO MOMETASONE FUROATE - 25 MCG/SPRAY
OLOPATADINE HCL EQV TO OLOPATADINE - 600 MCG/SPRAY

Dosage Form

SPRAY, SUSPENSION

Manufacturer and Country

GLENMARK PHARMACEUTICALS LIMITED (BADDI SITE) - INDIA
GLENMARK PHARMACEUTICALS LIMITED (CHHATRAPATI SAMBHAJINAGAR SITE) - INDIA

Registration Number

SIN16523P

Licence Holder

LOTUS INTERNATIONAL PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

R01AD59

INDICATIONS
RYALTRIS® is indicated for the treatment of moderate to severe symptoms associated with allergic rhinitis and rhinoconjunctivitis in patients 12 years of age and older.

DOSAGE AND ADMINISTRATION
Dosing Considerations
A relief of nasal allergic symptoms is observed within 10 minutes after administration of RYALTRIS®. However, since the full effect of RYALTRIS® depends on its regular use, patients must be instructed to take the nasal inhalation at regular intervals.

Recommended Dose and Dosage Adjustment
Adults and Adolescents (12 Years of Age and Older): The recommended dose of RYALTRIS® is two sprays in each nostril twice daily (morning and evening).

Administration
Administer RYALTRIS® by the intranasal route only. Avoid spraying RYALTRIS® into the eyes or mouth.
Shake the bottle well before each use.
Priming: Prime RYALTRIS® before initial use by releasing 6 sprays. When RYALTRIS® has not been used for 14 days or more, re-prime by releasing 2 sprays or until a fine mist appears.

Missed Dose
If a single dose is missed, the next dose should be taken when it is due. A double dose should not be taken at the same time.

CONTRAINDICATIONS
RYALTRIS® is contraindicated for patients who:

  • Are hypersensitive to this medicine or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see Qualitative and Quantitative Composition – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

  • Have untreated fungal, bacterial, or tuberculosis infections of the respiratory tract.